IN2014DN03429A - - Google Patents
Info
- Publication number
- IN2014DN03429A IN2014DN03429A IN3429DEN2014A IN2014DN03429A IN 2014DN03429 A IN2014DN03429 A IN 2014DN03429A IN 3429DEN2014 A IN3429DEN2014 A IN 3429DEN2014A IN 2014DN03429 A IN2014DN03429 A IN 2014DN03429A
- Authority
- IN
- India
- Prior art keywords
- inhibitor
- matrix
- allergene
- whereon
- adsorbed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11075261.5A EP2596802A1 (en) | 2011-11-23 | 2011-11-23 | Pharmaceutical composition for treatment of allergic reactions |
PCT/EP2012/004884 WO2013075846A1 (en) | 2011-11-23 | 2012-11-23 | Pharmaceutical composition for treatment of allergic reactions |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN03429A true IN2014DN03429A (xx) | 2015-06-05 |
Family
ID=47358079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3429DEN2014 IN2014DN03429A (xx) | 2011-11-23 | 2012-11-23 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20140335162A1 (xx) |
EP (1) | EP2596802A1 (xx) |
CN (1) | CN104039349A (xx) |
BR (1) | BR112014012277A2 (xx) |
IN (1) | IN2014DN03429A (xx) |
WO (1) | WO2013075846A1 (xx) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2813242A1 (en) * | 2013-06-13 | 2014-12-17 | PLS-Design GmbH | Low molecular weight immune-modulators as adjuvants for specific immunotherapy |
EP2918262B1 (en) * | 2014-03-10 | 2023-08-09 | PLS-Design GmbH | Induction of antigen-specific tolerance by peripheral phagocytosis |
CN116869964A (zh) * | 2014-12-24 | 2023-10-13 | 耐克西缪恩有限公司 | 用于免疫疗法的纳米颗粒组合物和方法 |
CN105727371B (zh) * | 2016-01-25 | 2019-04-09 | 北京天助畅运医疗技术股份有限公司 | 腹壁疝修补材料 |
CN107669638B (zh) * | 2017-10-23 | 2020-05-22 | 华南理工大学 | 一种peg-pcl-peg三嵌段共聚物修饰的羟基积雪草苷脂质体及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
US5126147A (en) * | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
DE4137333A1 (de) | 1991-11-13 | 1993-05-19 | W Prof Dr Sebald | Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung |
IL126995A0 (en) | 1996-06-14 | 1999-09-22 | Bayer Ag | T-cell selective interleukin-4 agonists |
US6028176A (en) | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
KR20010030891A (ko) | 1997-10-03 | 2001-04-16 | 마크로메드 인코퍼레이션 | 가역적 열 겔화 성질을 갖는 생분해성 저분자량 트리블럭폴리(락티드-코-글리콜리드) 폴리에틸렌 글리콜 공중합체 |
ID26963A (id) * | 1998-03-02 | 2001-02-22 | Applied Vaccine Technologies C | Metoda dan alat untuk memodulasi respon kekebalan |
CA2322435A1 (en) * | 1998-03-02 | 1999-09-10 | Applied Vaccine Technologies Corp. | Methods and devices for modulating the immune response |
US6841617B2 (en) * | 2000-09-28 | 2005-01-11 | Battelle Memorial Institute | Thermogelling biodegradable aqueous polymer solution |
WO2001039800A2 (en) * | 1999-12-06 | 2001-06-07 | The Board Of Trustees Of The University Of Arkansas | Controlled delivery of antigens |
EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
AU2001273413A1 (en) | 2000-07-12 | 2002-01-21 | Immunex Corporation | Method for treating cancer using an interleukin- 4 antagonist |
US20030003074A1 (en) | 2001-06-14 | 2003-01-02 | Macromed, Inc. | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
EP1785490B1 (en) | 2005-10-17 | 2007-11-14 | RiNA Netzwerk RNA-Technologien GmbH | Method for determining an unknown PNA sequence and uses thereof |
JP2009525267A (ja) * | 2006-01-11 | 2009-07-09 | アエロヴァンス インコーポレイティッド | ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物 |
AU2008314647B2 (en) * | 2007-10-12 | 2013-03-21 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
EP2604628A3 (en) | 2007-12-21 | 2013-08-21 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4R) - 173 |
CN102300558A (zh) * | 2009-01-28 | 2011-12-28 | 诺瓦提斯公司 | 有机化合物的盖伦制剂 |
JP5656370B2 (ja) | 2009-07-01 | 2015-01-21 | キヤノン株式会社 | 画像処理装置、画像処理システム、画像処理方法、およびプログラム |
-
2011
- 2011-11-23 EP EP11075261.5A patent/EP2596802A1/en not_active Withdrawn
-
2012
- 2012-11-23 WO PCT/EP2012/004884 patent/WO2013075846A1/en active Application Filing
- 2012-11-23 CN CN201280057730.4A patent/CN104039349A/zh active Pending
- 2012-11-23 US US14/360,343 patent/US20140335162A1/en not_active Abandoned
- 2012-11-23 BR BR112014012277A patent/BR112014012277A2/pt not_active IP Right Cessation
- 2012-11-23 IN IN3429DEN2014 patent/IN2014DN03429A/en unknown
-
2017
- 2017-11-06 US US15/804,532 patent/US20180117143A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180117143A1 (en) | 2018-05-03 |
CN104039349A (zh) | 2014-09-10 |
EP2596802A1 (en) | 2013-05-29 |
BR112014012277A2 (pt) | 2019-09-24 |
WO2013075846A1 (en) | 2013-05-30 |
US20140335162A1 (en) | 2014-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501306A1 (en) | Inhibitors of histone demethylases | |
PH12014501984A1 (en) | Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor | |
CO6771409A2 (es) | Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso | |
MX2012012438A (es) | Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina. | |
EP3354640A3 (en) | Mif inhibitors and their uses | |
MX2012003185A (es) | Composiciones farmaceuticas que comprenden bi-1356 y metformina. | |
MX2012012771A (es) | Terapia de combinacion. | |
PL2600865T3 (pl) | Związek użyteczny do leczenia chorób, w których pośredniczy mutacja nonsensowna oraz kompozycje farmaceutyczne zawierające wymieniony związek | |
MX338712B (es) | Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma. | |
BR112012032816A2 (pt) | composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz | |
UY33937A (es) | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina | |
MX345777B (es) | Formulaciones de tabletas bicapa. | |
IN2012DN02805A (xx) | ||
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
GB2503066B (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
TN2011000471A1 (en) | Pharmaceutical composition presenting anti-inflammatory properties | |
EA201071378A1 (ru) | Дронедарон для предотвращения постоянной фибрилляции предсердий | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
GB2497453B8 (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
CL2013001482A1 (es) | Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende. | |
IN2014DN03429A (xx) | ||
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
CL2012003265A1 (es) | Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo. |